186 related articles for article (PubMed ID: 34763504)
21. Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion.
Kitamura K; Kubota K; Ando M; Takahashi S; Nishijima N; Sugano T; Toyokawa M; Miwa K; Kosaihira S; Noro R; Minegishi Y; Seike M; Yoshimura A; Gemma A
Cancer Chemother Pharmacol; 2013 Feb; 71(2):457-61. PubMed ID: 23178954
[TBL] [Abstract][Full Text] [Related]
22. Effects of bevacizumab combined with oxaliplatin intrathoracic injection on tumor markers and survival rate in patients with malignant pleural effusion of lung cancer.
Chen X; Lu J; Yao Y; Huang Z; Liu K; Jiang W; Li C
Am J Transl Res; 2021; 13(4):2899-2906. PubMed ID: 34017454
[TBL] [Abstract][Full Text] [Related]
23. Role of bevacizumab in the management of the patient with malignant pleural effusion: more questions than answers.
Sabang RL; Gandhiraj D; Fanucchi M; Epelbaum O
Expert Rev Respir Med; 2018 Feb; 12(2):87-94. PubMed ID: 29235400
[TBL] [Abstract][Full Text] [Related]
24. [Progress of Bevacizumab in Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer].
Liu Y; Tian P
Zhongguo Fei Ai Za Zhi; 2019 Feb; 22(2):118-124. PubMed ID: 30827329
[TBL] [Abstract][Full Text] [Related]
25. [Clinical research on recombinant human Ad-p53 injection combined with cisplatin in treatment of malignant pleural effusion induced by lung cancer].
Zhao WZ; Wang JK; Li W; Zhang XL
Ai Zheng; 2009 Dec; 28(12):1324-7. PubMed ID: 19958629
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion.
Tao H; Meng Q; Li M; Shi L; Tang J; Liu Z
Thorac Cancer; 2018 Feb; 9(2):298-304. PubMed ID: 29297985
[TBL] [Abstract][Full Text] [Related]
27. Hyperthermic intrathoracic/intraperitoneal chemotherapy versus conventional intrapleural/intraperitoneal chemotherapy for the malignant effusion: a multi-center randomized clinical trial.
Liu L; Zhang T; Song X; Liao CG; Xu T; Yang Y; Zeng M; Jia J; Su H; Song Y; Min J; Zhang H; Li W; Zhang H; Zhang H
Int J Hyperthermia; 2023; 40(1):2241689. PubMed ID: 37574198
[TBL] [Abstract][Full Text] [Related]
28. Comparison between different treatment regimens of vascular targeting drug to malignant pleural effusion in patients with lung cancer: A Bayesian network meta-analysis.
Huang P; Guo ZK; Xue ZT
Medicine (Baltimore); 2023 Jul; 102(29):e34386. PubMed ID: 37478250
[TBL] [Abstract][Full Text] [Related]
29. [Report of two cases with pleural effusion and ascites that responded dramatically to the combination of thalidomide, celecoxib, irinotecan, and CDDP infused in thoracic and abdominal cavities].
Hada M
Gan To Kagaku Ryoho; 2004 Apr; 31(4):613-7. PubMed ID: 15114711
[TBL] [Abstract][Full Text] [Related]
30. The clinical efficacy and safety of paclitaxel combined with avastin for NSCLC patients diagnosed with malignant pleural effusion.
Wang Z; Zheng Y; Fang Z
Rev Assoc Med Bras (1992); 2018 Mar; 64(3):230-233. PubMed ID: 29641777
[TBL] [Abstract][Full Text] [Related]
31. Thoracic perfusion of recombinant mutant human tumor necrosis factor (rmhTNF) can be considered as a good adjunct in the treatment of malignant pleural effusion caused by lung cancer.
Fu T; Lin Y; Zeng Q; Yao W; Han L
BMC Pulm Med; 2020 Jun; 20(1):175. PubMed ID: 32552897
[TBL] [Abstract][Full Text] [Related]
32. Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group trial.
Rusch VW; Figlin R; Godwin D; Piantadosi S
J Clin Oncol; 1991 Feb; 9(2):313-9. PubMed ID: 1988578
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic evaluation of intrapleural perfusion with hyperthermic chemotherapy using cisplatin in patients with malignant pleural effusion.
Sakaguchi H; Ishida H; Nitanda H; Yamazaki N; Kaneko K; Kobayashi K
Lung Cancer; 2017 Feb; 104():70-74. PubMed ID: 28213004
[TBL] [Abstract][Full Text] [Related]
34. Intrapleural chemo- and hyperthermotherapies for malignant pleural effusion: a randomized prospective study.
Chen WJ; Yuan SF; Yan QY; Xiong JP; Wang SM; Zheng WE; Zhang W; Sun HY; Chen H; Wu LL
Cancer Invest; 2012 Feb; 30(2):126-30. PubMed ID: 22148972
[TBL] [Abstract][Full Text] [Related]
35. The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion.
Bradshaw M; Mansfield A; Peikert T
Curr Oncol Rep; 2013 Jun; 15(3):207-16. PubMed ID: 23568600
[TBL] [Abstract][Full Text] [Related]
36. [Comparison of the therapeutic effects of pleural perfusion of NDP and cDDP in NSCLC patients with malignant pleural effusion].
Cong YY; Liu MY; Cai L
Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):467-9. PubMed ID: 20819493
[TBL] [Abstract][Full Text] [Related]
37. [A Meta-Analysis of Efficacy and Adverse Effects of Lobaplatin and Cisplatin in the Treatment of Malignant Pleural Effusion].
Min S; Zheng Q; Zhang B; Yan D; Wang R; Qu Z; Li L; Liu J; Zhou Q
Zhongguo Fei Ai Za Zhi; 2019 Feb; 22(2):90-98. PubMed ID: 30827325
[TBL] [Abstract][Full Text] [Related]
38. Recombinant human endostatin (endostar) decreased recurrent ascites, pleural fluid and ascitic VEGF in a case of advanced mesothelioma.
Chen X; Liu Y; Yin Y; Jin S; Ping G; Røe OD; Yan K; Shu Y; Guo R
J Chemother; 2012 Aug; 24(4):231-6. PubMed ID: 23040690
[TBL] [Abstract][Full Text] [Related]
39. Intrapleural or intraperitoneal lobaplatin for treatment of patients with malignant pleural effusion or ascites.
Huang XE; Wei GL; Huo JG; Wang XN; Lu YY; Wu XY; Liu J; Xiang J; Feng JF
Asian Pac J Cancer Prev; 2013; 14(4):2611-4. PubMed ID: 23725184
[TBL] [Abstract][Full Text] [Related]
40. Intrapleural chemotherapy without pleurodesis for malignant pleural effusions. LCSG Trial 861.
Figlin R; Mendoza E; Piantadosi S; Rusch V
Chest; 1994 Dec; 106(6 Suppl):363S-366S. PubMed ID: 7988265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
